Related Experiment Videos
Partial fatty acid oxidation inhibitors for stable angina
1Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4970, USA. WCS4@po.cwru.edu
Expert Opinion on Investigational Drugs
|May 9, 2002
Summary
Partial inhibition of fatty acid oxidation offers effective therapy for chronic stable angina. This approach improves heart function during ischemia by enhancing glucose utilization and reducing lactate production.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- The heart primarily uses fatty acid oxidation for energy.
- Fatty acid oxidation inhibits glucose uptake and pyruvate oxidation.
- Myocardial ischemia impairs ATP production, leading to lactate buildup.
Purpose of the Study:
- To evaluate partial fatty acid oxidation inhibition as a therapy for chronic stable angina.
- To understand the metabolic effects of this inhibition on myocardial function during ischemia.
Main Methods:
- Review of clinical trials involving ranolazine and trimetazidine.
- Analysis of the effects of fatty acid oxidation inhibition on myocardial metabolism.
Main Results:
- Partial inhibition of fatty acid oxidation enhances glucose and pyruvate oxidation.
- This metabolic shift reduces lactate production, improving myocardial pH and contractile function during ischemia.
- Agents like ranolazine and trimetazidine demonstrated reduced exercise-induced angina symptoms.
Conclusions:
- Partial fatty acid oxidation inhibition is an effective treatment for chronic stable angina, especially in patients with persistent symptoms.
- This therapeutic strategy improves cardiac energy metabolism during ischemia without affecting heart rate or blood pressure.